Memorial Sloan-Kettering has been praised for taking a stand on the price for a new cancer drug that costs more than twice as much as another, similar drug.

Dr. Shah, Chief of the Head and Neck Service, discusses how Memorial Sloan-Kettering’s world-renowned head and neck surgeons partner with patients to select the most appropriate treatment plan.

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

Dr. Abu-Rustum, Director of Minimally Invasive Surgery for the Gynecology Service, discusses how the gynecologic cancer care team treats each woman with an individualized approach.

When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Dr. Finley, Co-Director of the Complex Airway Program, explains how he lays out a treatment plan with his patients, and determines which type of surgery fits best in the context of their lifestyle.